文献速递前列腺癌

首次监测活检中前列腺癌不良重分类的时间:来自Canary前列腺癌主动监测研究的结果

Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study.
PubMed 文献 · J Urol · 2016-11-01

研究分析Canary PASS中421例低危前列腺癌主动监测患者,首次监测活检距诊断<8、8-13、>13个月的重分类率分别为24%、19%、22%(p=0.65),多因素分析示活检时机与重分类无显著关联;PSA密度≥0.15(OR 1.9,95%CI 1.1-4.1)和BMI≥35 kg/m²(OR 2.4,95%CI 1.1-5.7)与重分类风险升高相关。作者认为低危患者可考虑推迟首次监测活检。

要点

  • 首次监测活检距诊断<8、8-13、>13个月的重分类率分别为24%、19%、22%(p=0.65)。
  • 与<8个月活检者相比,8-13个月和>13个月活检的OR分别为0.88(95%CI 0.5-1.6)和0.95(95%CI 0.5-1.9)。
  • PSA密度≥0.15(OR 1.9,95%CI 1.1-4.1)和BMI≥35 kg/m²(OR 2.4,95%CI 1.1-5.7)与重分类风险升高相关。

核心结论

  • 首次主动监测活检的时机与不良重分类风险升高无关,而PSA密度和BMI与重分类风险相关。
  • 作者认为,对于主动监测中的低危患者,在较晚时间进行首次主动监测活检可能是合理的,可降低主动监测的总体成本和并发症。

研究设计与样本

  • Canary PASS(前列腺癌主动监测研究)队列分析,纳入1,085例参与者中的421例。
  • 421例患者活检受癌组织芯数<34%且Gleason评分≤6,随后接受研究内主动监测活检。
  • 重分类定义为Gleason评分升高和/或≥34%的活检芯受癌组织累及。
  • 首次主动监测活检按诊断后<8个月、8-13个月和>13个月分组。
  • 采用多因素logistic回归分析重分类与首次活检时机的关联。

主要发现

  • 421例中89例(21.1%)在首次主动监测活检时发生重分类。
  • 前列腺癌诊断至首次主动监测活检的中位时间为11个月(IQR 7.8-13.8)。
  • 首次活检距诊断<8、8-13和>13个月的重分类率分别为24%、19%和22%(p=0.65)。
  • 与<8个月活检者相比,8-13个月和>13个月活检的重分类OR分别为0.88(95%CI 0.5-1.6)和0.95(95%CI 0.5-1.9)。
  • PSA密度≥0.15(参照<0.15,OR 1.9,95%CI 1.1-4.1)和BMI≥35 kg/m²(参照<25 kg/m²,OR 2.4,95%CI 1.1-5.7)与重分类风险升高相关。

临床怎么用

  • 作者认为,对于主动监测中的低危患者,在较晚时间进行首次主动监测活检可能是合理的,可降低主动监测的总体成本和并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: During active surveillance for localized prostate cancer, the timing of the first surveillance biopsy varies. We analyzed the Canary PASS (Prostate Cancer Active Surveillance Study) to determine biopsy timing influence on rates of prostate cancer adverse reclassification at the first active surveillance biopsy. MATERIALS AND METHODS: Of 1,085 participants in PASS, 421 had fewer than 34% of cores involved with cancer and Gleason sum 6 or less, and thereafter underwent on-study active surveillance biopsy. Reclassification was defined as an increase in Gleason sum and/or 34% or more of cores with prostate cancer. First active surveillance biopsy reclassification rates were categorized as less than 8, 8 to 13 and greater than 13 months after diagnosis. Multivariable logistic regression determined association between reclassification and first biopsy timing. RESULTS: Of 421 men, 89 (21.1%) experienced reclassification at the first active surveillance biopsy. Median time from prostate cancer diagnosis to first active surveillance biopsy was 11 months (IQR 7.8-13.8). Reclassification rates at less than 8, 8 to 13 and greater than 13 months were 24%, 19% and 22% (p = 0.65). On multivariable analysis, compared to men biopsied at less than 8 months the OR of reclassification at 8 to 13 and greater than 13 months were 0.88 (95% CI 0.5,1.6) and 0.95 (95% CI 0.5,1.9), respectively. Prostate specific antigen density 0.15 or greater (referent less than 0.15, OR 1.9, 95% CI 1.1, 4.1) and body mass index 35 kg/m2 or greater (referent less than 25 kg/m2, OR 2.4, 95% CI 1.1,5.7) were associated with increased odds of reclassification. CONCLUSIONS: Timing of the first active surveillance biopsy was not associated with increased adverse reclassification but prostate specific antigen density and body mass index were. In low risk patients on active surveillance, it may be reasonable to perform the first active surveillance biopsy at a later time, reducing the overall cost and morbidity of active surveillance.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Macleod LC, Ellis WJ, Newcomb LF, et al. Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. J Urol. 2016. PMID: 27810448. doi:10.1016/j.juro.2016.10.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。